Acceptance of SARS-CoV-2 vaccination among cancer patients in Portugal: attitudes and associated factors.
Acceptance
COVID-19
Cancer
Vaccination
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
17
10
2021
accepted:
28
01
2022
pubmed:
5
2
2022
medline:
26
3
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
COVID-19 vaccines have shown efficacy and safety in healthy people. However, cancer patients under active immunosuppressive treatment were not included in the clinical trials conducted to test vaccines' efficacy and safety. This study aimed to evaluate the COVID-19 vaccine acceptance in cancer patients undergoing immunosuppressive therapy. A total of 200 adult cancer patients received a questionnaire between March 8 and April 2, 2021, before the beginning of cancer patients' vaccination in Portugal. The questionnaire adapted from previously conducted studies included 11 close-ended items, evaluating variables such as patient sociodemographic and clinical characteristics, and the acceptance and underlying reasons to be or not to be vaccinated. The primary outcome was the intended acceptance of the COVID-19 vaccine in cancer patients. Multiple logistic regression was performed to identify factors associated with intended acceptance. Among the 200 delivered questionnaires, only 169 were included in this study. From those, 142 (84%) patients intended to be vaccinated against COVID-19. Only 27 participants (16%) had not yet decided or were reluctant to COVID-19 vaccination. High school degree (odds ratio (OR) 0.133, 95% confidence interval (C.I.) 0.031-0.579, p = 0.007], rural residence (OR 0.282, 95% C.I. 0.081-0.984, p = 0.047), and reluctance in believing in the vaccine efficacy (OR 0.058, 95% C.I. 0.016-0.204, p < 0.001] were identified predictors factor for COVID-19 vaccine hesitancy. Most patients intended to be vaccinated against COVID-19, and specific factors such as education level, rural residence and the belief in vaccine efficacy were related to vaccine acceptance.
Identifiants
pubmed: 35119521
doi: 10.1007/s00520-022-06886-x
pii: 10.1007/s00520-022-06886-x
pmc: PMC8815020
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4565-4570Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
World Health Organization (2021) Weekly epidemiological update on COVID-19 - 28 September 2021. In: Emerg. Situational Updat. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19%2D%2D-28-september-2021 . Accessed 1 Oct 2021
Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner N, Köhler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M et al (2021) COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol 100:383–393. https://doi.org/10.1007/S00277-020-04328-4
doi: 10.1007/S00277-020-04328-4
pubmed: 33159569
Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall MW, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX et al (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 21:1309–1316. https://doi.org/10.1016/S1470-2045(20)30442-3
doi: 10.1016/S1470-2045(20)30442-3
pubmed: 32853557
pmcid: 7444972
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, McCarthy CG, Falcon CJ, Schoenfeld AJ, Arbour KC, Chaft JE, Daly RM, Drilon A, Eng J, Iqbal A, Lai WV, Li BT, Lito P, Namakydoust A et al (2020) COVID-19 in patients with lung cancer. Ann Oncol 31:1386. https://doi.org/10.1016/J.ANNONC.2020.06.007
doi: 10.1016/J.ANNONC.2020.06.007
pubmed: 32561401
Baden LR, Sahly HM El, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T (2020) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. 384:403–416 . https://doi.org/10.1056/NEJMOA2035389
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina W V., Cooper D, Robert W. Frenck J, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. 383:2603–2615. https://doi.org/10.1056/NEJMOA2034577
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111. https://doi.org/10.1016/S0140-6736(20)32661-1
doi: 10.1016/S0140-6736(20)32661-1
pubmed: 33306989
pmcid: 7723445
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN et al (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397:671–681. https://doi.org/10.1016/S0140-6736(21)00234-8
doi: 10.1016/S0140-6736(21)00234-8
pubmed: 33545094
pmcid: 7852454
Garassino MC, Giesen N, Grivas P, Jordan K, Lucibello F, Mir O, Pentheroudakis G, LastNameLastNameLastNamScotté F (2021) COVID-19 vaccination in cancer patients: ESMO statements. https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination . Accessed 1 Oct 2021
Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S (2021) The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor Educate Ann Oncol 32:579–581. https://doi.org/10.1016/J.ANNONC.2021.01.068
doi: 10.1016/J.ANNONC.2021.01.068
pubmed: 33582237
Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A (2021) Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. Front Public Heal 0:1152. https://doi.org/10.3389/FPUBH.2021.698111
doi: 10.3389/FPUBH.2021.698111
Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, Exel J van, Schreyögg J, Stargardt T (2020) Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ 21:977–982 . https://doi.org/10.1007/S10198-020-01208-6
Barrière J, Gal J, Hoch B, Cassuto O, Leysalle A, Chamorey E, Borchiellini D (2021) Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol 32:673–674. https://doi.org/10.1016/J.ANNONC.2021.01.066
doi: 10.1016/J.ANNONC.2021.01.066
pubmed: 33529740
Villarreal-Garza C, Vaca-Cartagena BF, Becerril-Gaitan A, Ferrigno AS, Mesa-Chavez F, Platas A, Platas A (2021) Attitudes and factors associated with COVID-19 vaccine hesitancy among patients with breast cancer. JAMA Oncol 7:1242–1244. https://doi.org/10.1001/JAMAONCOL.2021.1962
doi: 10.1001/JAMAONCOL.2021.1962
pubmed: 34110371
Chan W-L, Ho Y-HT, Wong CK-H, Choi HC-W, Lam K-O, Yuen K-K, Kwong D, Hung I (2021) Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines 9:792. https://doi.org/10.3390/VACCINES9070792
doi: 10.3390/VACCINES9070792
pubmed: 34358208
pmcid: 8310340
Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W (2021) Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine 40:101113. https://doi.org/10.1016/J.ECLINM.2021.101113
doi: 10.1016/J.ECLINM.2021.101113
pubmed: 34490416
pmcid: 8411034
Alqudeimat Y, Alenezi D, AlHajri B, Alfouzan H, Almokhaizeem Z, Altamimi S, Almansouri W, Alzalzalah S, Ziyab AH (2021) Acceptance of a COVID-19 vaccine and its related determinants among the general adult population in Kuwait. Med Princ Pract 30:262–271. https://doi.org/10.1159/000514636
doi: 10.1159/000514636
pubmed: 33486492
pmcid: 8089409